AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Change in Fair Value of Contingent Consideration by Year
Change in Fair Value of Contingent Consideration — After-Tax ($M) ($M)
AbbVie Change in Fair Value of Contingent Consideration: $6,309M in FY2025, up 71.8% from a year earlier.
Latest, FY2025
6,309
Period ended Dec 31, 2025
Change on a year earlier
+71.8%
3,673 in FY2024
History
4 years
Since FY2022
Sources
4
Documents cited below
Where the FY2025 figure comes from
“|| Change in fair value of contingent consideration | 6,495 | 6,309 | 3.56”
Source: Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Reported in Form 8-K Non-GAAP Reconciliations.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Change in Fair Value of Contingent Consideration — After-Tax ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6,309 | +71.8% | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| FY2024 | Dec 31, 2024 | 3,673 | -26.6% | Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗ |
| FY2023 | Dec 31, 2023 | 5,003 | +80.6% | Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗ |
| FY2022 | Dec 31, 2022 | 2,770 | – | Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗ |
Cite this data
StockData. (2026). AbbVie Change in Fair Value of Contingent Consideration ($M), annual FY2022–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/nongaap-spec-cc-aftertax
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.